Details of the Drug

General Information of Drug (ID: DMGB035)

Drug Name
Armodafinil
Synonyms
Nuvigil; 112111-43-0; (R)-Modafinil; (R)-(-)-Modafinil; CEP-10953; UNII-V63XWA605I; CRL 40982; CEP 10953; V63XWA605I; CHEMBL1201192; CHEBI:77590; 2-[(R)-(Diphenylmethyl)sulfinyl]acetamide; (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide; (-)-2-[(r)-(diphenylmethyl)sulfinyl]acetamide; Armodafinil [USAN:INN]; armodafinilo; armodafinilum; l-Modafinil; Nuvigil (TN); (-)-(R)-modafinil; Armodafinil (USAN/INN); SCHEMBL34489; ZINC6156; ACE037; Armodafinil, > YFGHCGITMMYXAQ-LJQANCHMSA-N
Indication
Disease Entry ICD 11 Status REF
Pediatric cancer 2A00-2F9Z Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 273.4
Topological Polar Surface Area (xlogp) 1.7
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Clearance
The apparent oral clearance of drug is 33 mL/min [3]
Elimination
8% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 15 hours [4]
Metabolism
The drug is metabolized via the cytochrome P450 (CYP) 3A4/5 [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 13.0649 micromolar/kg/day [6]
Vd
The volume of distribution (Vd) of drug is 42 L [3]
Chemical Identifiers
Formula
C15H15NO2S
IUPAC Name
2-[(R)-benzhydrylsulfinyl]acetamide
Canonical SMILES
C1=CC=C(C=C1)C(C2=CC=CC=C2)[S@](=O)CC(=O)N
InChI
InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1
InChIKey
YFGHCGITMMYXAQ-LJQANCHMSA-N
Cross-matching ID
PubChem CID
9690109
ChEBI ID
CHEBI:77590
CAS Number
112111-43-0
DrugBank ID
DB06413
TTD ID
D0J5RN
VARIDT ID
DR00998
INTEDE ID
DR0137
ACDINA ID
D00044

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Agonist [7], [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Armodafinil
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Increased metabolism of Armodafinil caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [38]
LEE011 DMMX75K Moderate Increased metabolism of Armodafinil caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [38]
Coadministration of a Drug Treating the Disease Different from Armodafinil (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Armodafinil caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [39]
Midostaurin DMI6E0R Moderate Increased metabolism of Armodafinil caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [40]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Armodafinil caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [41]
Oliceridine DM6MDCF Major Increased metabolism of Armodafinil caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [42]
Ivabradine DM0L594 Moderate Increased metabolism of Armodafinil caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [43]
Bedaquiline DM3906J Minor Increased metabolism of Armodafinil caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [44]
Troleandomycin DMUZNIG Minor Decreased metabolism of Armodafinil caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [38]
Erdafitinib DMI782S Moderate Decreased clearance of Armodafinil due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [45]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Armodafinil caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [46]
HKI-272 DM6QOVN Minor Increased metabolism of Armodafinil caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
LY2835219 DM93VBZ Moderate Increased metabolism of Armodafinil caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Esterified estrogens DM9KZDO Minor Increased metabolism of Armodafinil caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Tucatinib DMBESUA Minor Decreased metabolism of Armodafinil caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [38]
Palbociclib DMD7L94 Moderate Increased metabolism of Armodafinil caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [38]
Alpelisib DMEXMYK Moderate Increased metabolism of Armodafinil caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Cabazitaxel DMPAZHC Minor Increased metabolism of Armodafinil caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Bosutinib DMTI8YE Moderate Increased metabolism of Armodafinil caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [49]
Macitentan DMP79A1 Minor Increased metabolism of Armodafinil caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [44]
PF-04449913 DMSB068 Moderate Increased metabolism of Armodafinil caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [50]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Armodafinil caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [38]
Ulipristal DMBNI20 Moderate Increased metabolism of Armodafinil caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [43]
Osilodrostat DMIJC9X Moderate Increased metabolism of Armodafinil caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [51]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Armodafinil caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [39]
Ivacaftor DMZC1HS Minor Decreased metabolism of Armodafinil caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [38]
MK-8228 DMOB58Q Minor Decreased metabolism of Armodafinil caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [38]
Vilazodone DM4LECQ Minor Increased metabolism of Armodafinil caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [44]
OPC-34712 DMHG57U Minor Increased metabolism of Armodafinil caused by OPC-34712 mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [44]
Esketamine DMVU687 Major Additive hypertensive effects by the combination of Armodafinil and Esketamine. Depression [6A70-6A7Z] [38]
Oestradiol valerate and dienogest DMZK0FQ Moderate Increased metabolism of Armodafinil caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [52]
Stiripentol DMMSDOY Moderate Increased metabolism of Armodafinil caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Armodafinil caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Armodafinil caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [53]
Tazemetostat DMWP1BH Moderate Increased metabolism of Armodafinil caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [54]
Mirabegron DMS1GYT Minor Increased metabolism of Armodafinil caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [55]
Ripretinib DM958QB Moderate Increased metabolism of Armodafinil caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [38]
Avapritinib DMK2GZX Moderate Increased metabolism of Armodafinil caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [43]
Boceprevir DMBSHMF Minor Decreased metabolism of Armodafinil caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [38]
GS-5885 DMSL3DX Moderate Decreased clearance of Armodafinil due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [56]
MK-1439 DM215WE Moderate Increased metabolism of Armodafinil caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [57]
Fostemsavir DM50ILT Minor Increased metabolism of Armodafinil caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Cobicistat DM6L4H2 Moderate Increased metabolism of Armodafinil caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [42]
Dolutegravir DMCZGRE Minor Increased metabolism of Armodafinil caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [44]
Etravirine DMGV8QU Moderate Increased metabolism of Armodafinil caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [59]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Armodafinil caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
BMS-201038 DMQTAGO Moderate Decreased clearance of Armodafinil due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [60]
Levamlodipine DM92S6N Minor Increased metabolism of Armodafinil caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [44]
Lesinurad DMUR64T Moderate Increased metabolism of Armodafinil caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [39]
Suvorexant DM0E6S3 Minor Decreased metabolism of Armodafinil caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [38]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Armodafinil caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [61]
Naloxegol DML0B41 Minor Increased metabolism of Armodafinil caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [44]
Pemigatinib DM819JF Moderate Increased metabolism of Armodafinil caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [43]
Crizotinib DM4F29C Minor Decreased metabolism of Armodafinil caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [38]
Brigatinib DM7W94S Moderate Increased metabolism of Armodafinil caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [38]
Ceritinib DMB920Z Moderate Increased metabolism of Armodafinil caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [62]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Armodafinil caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [63]
PF-06463922 DMKM7EW Moderate Increased metabolism of Armodafinil caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [39]
Osimertinib DMRJLAT Moderate Increased metabolism of Armodafinil caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [64]
Capmatinib DMYCXKL Moderate Decreased clearance of Armodafinil due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [65]
Selpercatinib DMZR15V Moderate Increased metabolism of Armodafinil caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [43]
Artemether DM48QOT Moderate Increased metabolism of Armodafinil caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [38]
Idelalisib DM602WT Minor Decreased metabolism of Armodafinil caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [38]
GDC-0199 DMH0QKA Moderate Increased metabolism of Armodafinil caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [66]
IPI-145 DMWA24P Moderate Increased metabolism of Armodafinil caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [67]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Armodafinil caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [68]
Ibrutinib DMHZCPO Minor Increased metabolism of Armodafinil caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [44]
Ponatinib DMYGJQO Minor Increased metabolism of Armodafinil caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [44]
Vemurafenib DM62UG5 Moderate Increased metabolism of Armodafinil caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [69]
Selumetinib DMC7W6R Moderate Increased metabolism of Armodafinil caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [70]
LGX818 DMNQXV8 Moderate Increased metabolism of Armodafinil caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [71]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Armodafinil caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [43]
Ubrogepant DM749I3 Moderate Increased metabolism of Armodafinil caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [72]
Lasmiditan DMXLVDT Moderate Decreased clearance of Armodafinil due to the transporter inhibition by Lasmiditan. Migraine [8A80] [73]
Panobinostat DM58WKG Moderate Increased metabolism of Armodafinil caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [74]
Ruxolitinib DM7Q98D Minor Increased metabolism of Armodafinil caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [44]
Rolapitant DM8XP26 Moderate Increased metabolism of Armodafinil caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [75]
Netupitant DMEKAYI Minor Decreased metabolism of Armodafinil caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [38]
Entrectinib DMMPTLH Moderate Increased metabolism of Armodafinil caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [76]
S-297995 DM26IH8 Minor Increased metabolism of Armodafinil caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [44]
Olaparib DM8QB1D Major Increased metabolism of Armodafinil caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [38]
Rucaparib DM9PVX8 Minor Decreased metabolism of Armodafinil caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [38]
Istradefylline DM20VSK Minor Increased metabolism of Armodafinil caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [44]
Abametapir DM2RX0I Moderate Decreased metabolism of Armodafinil caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [77]
Macimorelin DMQYJIR Moderate Increased metabolism of Armodafinil caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [78]
Lefamulin DME6G97 Moderate Increased metabolism of Armodafinil caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [79]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Armodafinil caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [80]
Enzalutamide DMGL19D Moderate Increased metabolism of Armodafinil caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [81]
Darolutamide DMV7YFT Moderate Increased metabolism of Armodafinil caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [82]
Riociguat DMXBLMP Minor Increased metabolism of Armodafinil caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [44]
Axitinib DMGVH6N Moderate Increased metabolism of Armodafinil caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [83]
Upadacitinib DM32B5U Minor Increased metabolism of Armodafinil caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [44]
Tofacitinib DMBS370 Minor Increased metabolism of Armodafinil caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [44]
LDE225 DMM9F25 Moderate Increased metabolism of Armodafinil caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [84]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Armodafinil caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [43]
Fostamatinib DM6AUHV Moderate Increased metabolism of Armodafinil caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [85]
Apixaban DM89JLN Minor Increased metabolism of Armodafinil caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [44]
Brilinta DMBR01X Moderate Increased metabolism of Armodafinil caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [42]
Cabozantinib DMIYDT4 Moderate Increased metabolism of Armodafinil caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [86]
Linagliptin DMWFJTR Moderate Increased metabolism of Armodafinil caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [87]
Elagolix DMB2C0E Moderate Increased metabolism of Armodafinil caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [88]
⏷ Show the Full List of 99 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium stearyl fumarate E00545 23665634 lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Armodafinil 100 mg tablet 100 mg Oral Tablet Oral
Armodafinil 150 mg tablet 150 mg Oral Tablet Oral
Armodafinil 200 mg tablet 200 mg Oral Tablet Oral
Armodafinil 250 mg tablet 250 mg Oral Tablet Oral
Armodafinil 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS applied to over 900 drugs
3 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
8 US patent application no. 2014,0349,964, Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder.
9 Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74.
10 Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123-37.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
21 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
22 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
23 Drug Interactions Flockhart Table
24 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
25 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
26 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
27 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
28 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
29 The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
30 Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
31 Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
32 Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
33 Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
34 The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
35 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
36 Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
37 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
38 Cerner Multum, Inc. "Australian Product Information.".
39 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
40 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
41 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
42 Canadian Pharmacists Association.
43 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
44 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
45 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
46 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
47 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
48 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
49 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
50 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
51 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
52 Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
53 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
54 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
55 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
56 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
57 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
58 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
59 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
60 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
61 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
62 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
63 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
64 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
65 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
66 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
67 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
68 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
69 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
70 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
71 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
72 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
73 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
74 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
75 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
76 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
77 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
78 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
79 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
80 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
81 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
82 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
83 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
84 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
85 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
86 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
87 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
88 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.